Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.9K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.9K
Replication in Eukaryotes02:31

Replication in Eukaryotes

200.9K
Overview
200.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Respiratory virus genomic epidemiology during post-pandemic re-emergence of influenza in Australia.

Virus evolution·2026
Same author

Ecology of Low Pathogenicity Avian Influenza Virus H7 in Wild Birds in South-Eastern Australia Prior to Emergence of High Pathogenicity Avian Influenza H7 in Poultry.

Influenza and other respiratory viruses·2026
Same author

Surveillance of Migratory Shorebirds and Seabirds in 2024 in Australia Reveals Incursions of a Diversity of Low Pathogenicity Avian Influenza Viruses, but Not High Pathogenicity Avian Influenza H5N1.

Influenza and other respiratory viruses·2026
Same author

Immunogenicity of high-dose recombinant influenza vaccine versus standard-dose egg-grown and cell-grown vaccines among frequently and infrequently vaccinated young adults in Singapore: a randomised, controlled, double-blind, single-centre, phase 4 clinical trial.

The Lancet. Infectious diseases·2026
Same author

The Development of Global Genomic Surveillance of Respiratory Syncytial Virus: Insights From 25 Project Countries, 2019-2023.

Influenza and other respiratory viruses·2026
Same author

Genomic evidence of HMPV resurgence in Beijing: Clade B2 triggers the 2024 winter epidemic peak.

Virologica Sinica·2026

Related Experiment Video

Updated: Dec 16, 2025

Influenza Virus Propagation in Embryonated Chicken Eggs
06:56

Influenza Virus Propagation in Embryonated Chicken Eggs

Published on: March 19, 2015

44.7K

SARS-CoV-2 does not replicate in embryonated hen's eggs or in MDCK cell lines.

Ian G Barr1,2,3, Cleve Rynehart1, Paul Whitney1,2

  • 1The WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.

Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin
|July 3, 2020
PubMed
Summary

The study investigated if SARS-CoV-2 could contaminate influenza vaccine production. Researchers found that neither embryonated hen

Keywords:
Influenza, SARS-CoV-2, vaccine, respiratory, air-borne infections, viral infections, influenzasevere acute respiratory syndrome – SARS, influenza virus, biosafety, vaccines and immunisation, laboratory

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.2K
An Ex Vivo Chicken Primary Bursal-cell Culture Model to Study Infectious Bursal Disease Virus Pathogenesis
07:26

An Ex Vivo Chicken Primary Bursal-cell Culture Model to Study Infectious Bursal Disease Virus Pathogenesis

Published on: October 4, 2018

9.3K

Related Experiment Videos

Last Updated: Dec 16, 2025

Influenza Virus Propagation in Embryonated Chicken Eggs
06:56

Influenza Virus Propagation in Embryonated Chicken Eggs

Published on: March 19, 2015

44.7K
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.2K
An Ex Vivo Chicken Primary Bursal-cell Culture Model to Study Infectious Bursal Disease Virus Pathogenesis
07:26

An Ex Vivo Chicken Primary Bursal-cell Culture Model to Study Infectious Bursal Disease Virus Pathogenesis

Published on: October 4, 2018

9.3K

Area of Science:

  • Virology
  • Vaccine Production
  • Public Health

Background:

  • The emergence of COVID-19 raises concerns about potential co-infection with influenza viruses in human respiratory samples.
  • Influenza vaccine production relies on substrates like embryonated hen's eggs and cell lines, which could theoretically be contaminated by SARS-CoV-2.
  • Ensuring the safety of influenza vaccine manufacturing processes is critical during the COVID-19 pandemic.

Purpose of the Study:

  • To assess the risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) contamination in influenza vaccine production.
  • To determine if common substrates used for influenza vaccine manufacturing can support SARS-CoV-2 replication.

Main Methods:

  • Inoculation of embryonated hen's eggs with SARS-CoV-2.
  • Inoculation of continuous cell lines used in influenza vaccine production with SARS-CoV-2.
  • Monitoring of viral propagation in both substrates.

Main Results:

  • SARS-CoV-2 did not replicate in embryonated hen's eggs.
  • SARS-CoV-2 did not propagate in the continuous cell lines utilized for influenza vaccine isolation and production.
  • The tested substrates do not support SARS-CoV-2 replication.

Conclusions:

  • Conventional influenza vaccine production platforms are unlikely to be contaminated by SARS-CoV-2.
  • The risk of SARS-CoV-2 contaminating influenza vaccines due to substrate permissiveness is negligible.
  • This finding supports the continued safe production of influenza vaccines during the COVID-19 pandemic.